Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 4 | 2021 | 225 | 2.180 |
Why?
|
| Radiation Tolerance | 4 | 2019 | 90 | 1.420 |
Why?
|
| Inflammatory Breast Neoplasms | 3 | 2017 | 4 | 1.350 |
Why?
|
| Gastrula | 2 | 2017 | 5 | 1.190 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 102 | 1.180 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 19 | 1.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 1027 | 1.150 |
Why?
|
| Tumor Burden | 3 | 2020 | 144 | 1.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2020 | 28 | 1.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 89 | 1.020 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 213 | 1.010 |
Why?
|
| Endoderm | 2 | 2017 | 5 | 0.790 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 121 | 0.790 |
Why?
|
| Neutrophils | 1 | 2021 | 163 | 0.780 |
Why?
|
| Embryo, Mammalian | 2 | 2017 | 72 | 0.780 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 125 | 0.750 |
Why?
|
| Cell Movement | 2 | 2016 | 300 | 0.700 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2017 | 14 | 0.700 |
Why?
|
| Cell Line, Tumor | 9 | 2020 | 1504 | 0.700 |
Why?
|
| Forkhead Transcription Factors | 2 | 2015 | 118 | 0.680 |
Why?
|
| Melanoma | 1 | 2021 | 319 | 0.680 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 158 | 0.660 |
Why?
|
| Homeodomain Proteins | 2 | 2017 | 83 | 0.660 |
Why?
|
| Paracrine Communication | 1 | 2016 | 18 | 0.640 |
Why?
|
| Macrophages | 2 | 2017 | 412 | 0.630 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 1274 | 0.610 |
Why?
|
| Simvastatin | 1 | 2015 | 35 | 0.590 |
Why?
|
| Repressor Proteins | 1 | 2017 | 171 | 0.570 |
Why?
|
| Lipoproteins, VLDL | 1 | 2015 | 17 | 0.570 |
Why?
|
| Interleukin-6 | 1 | 2016 | 318 | 0.560 |
Why?
|
| MicroRNAs | 2 | 2016 | 366 | 0.550 |
Why?
|
| Mutation | 1 | 2021 | 1432 | 0.550 |
Why?
|
| Internship and Residency | 1 | 2020 | 493 | 0.550 |
Why?
|
| Mice, SCID | 3 | 2020 | 201 | 0.500 |
Why?
|
| Inflammation | 1 | 2016 | 671 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 597 | 0.440 |
Why?
|
| Deoxycytidine | 2 | 2020 | 30 | 0.410 |
Why?
|
| Albumins | 2 | 2020 | 33 | 0.410 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 133 | 0.400 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1290 | 0.400 |
Why?
|
| Paclitaxel | 2 | 2020 | 101 | 0.390 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 464 | 0.380 |
Why?
|
| Humans | 18 | 2021 | 53032 | 0.340 |
Why?
|
| Female | 13 | 2021 | 28983 | 0.340 |
Why?
|
| Animals | 8 | 2020 | 14806 | 0.290 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 3642 | 0.290 |
Why?
|
| Cell Proliferation | 3 | 2020 | 1128 | 0.270 |
Why?
|
| Mice, Nude | 3 | 2020 | 278 | 0.270 |
Why?
|
| Middle Aged | 6 | 2021 | 13685 | 0.260 |
Why?
|
| Mice | 6 | 2019 | 6403 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 895 | 0.250 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 810 | 0.220 |
Why?
|
| Cell Cycle | 2 | 2020 | 280 | 0.210 |
Why?
|
| Caveolin 1 | 1 | 2020 | 22 | 0.210 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 100 | 0.200 |
Why?
|
| Faculty | 1 | 2020 | 72 | 0.200 |
Why?
|
| Leucovorin | 1 | 2020 | 22 | 0.200 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 255 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 69 | 0.200 |
Why?
|
| Phosphorylation | 3 | 2017 | 644 | 0.200 |
Why?
|
| Fluorouracil | 1 | 2020 | 75 | 0.200 |
Why?
|
| Lymphocytes | 1 | 2021 | 174 | 0.200 |
Why?
|
| Radiation Dosage | 1 | 2021 | 174 | 0.200 |
Why?
|
| Coculture Techniques | 2 | 2017 | 163 | 0.190 |
Why?
|
| Spleen | 1 | 2021 | 200 | 0.190 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 428 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 130 | 0.190 |
Why?
|
| Linear Models | 1 | 2020 | 322 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2019 | 52 | 0.180 |
Why?
|
| Tumor Microenvironment | 2 | 2017 | 144 | 0.180 |
Why?
|
| Male | 7 | 2021 | 28343 | 0.180 |
Why?
|
| Survival Rate | 3 | 2019 | 1016 | 0.180 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 87 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 537 | 0.180 |
Why?
|
| Retrospective Studies | 2 | 2021 | 6076 | 0.180 |
Why?
|
| Interleukin-13 | 1 | 2017 | 16 | 0.170 |
Why?
|
| STAT6 Transcription Factor | 1 | 2017 | 9 | 0.170 |
Why?
|
| Cell Polarity | 1 | 2017 | 18 | 0.170 |
Why?
|
| Interleukin-4 | 1 | 2017 | 51 | 0.170 |
Why?
|
| Aged | 3 | 2021 | 10476 | 0.170 |
Why?
|
| DNA Repair | 2 | 2019 | 217 | 0.170 |
Why?
|
| Protein Kinase C | 1 | 2017 | 79 | 0.170 |
Why?
|
| Allantois | 1 | 2017 | 1 | 0.170 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2017 | 1 | 0.170 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2017 | 3 | 0.170 |
Why?
|
| Fetal Proteins | 1 | 2017 | 5 | 0.160 |
Why?
|
| Mice, Knockout | 1 | 2020 | 1006 | 0.160 |
Why?
|
| T-Box Domain Proteins | 1 | 2017 | 16 | 0.160 |
Why?
|
| Adult | 4 | 2021 | 14382 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 181 | 0.160 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2016 | 12 | 0.160 |
Why?
|
| Signal Transduction | 2 | 2016 | 1850 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 157 | 0.160 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2017 | 50 | 0.160 |
Why?
|
| Cell Survival | 2 | 2019 | 695 | 0.160 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5645 | 0.160 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 119 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 84 | 0.160 |
Why?
|
| Cell Dedifferentiation | 1 | 2016 | 10 | 0.160 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 435 | 0.150 |
Why?
|
| Placenta | 1 | 2017 | 111 | 0.150 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 55 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 329 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 303 | 0.150 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2015 | 21 | 0.140 |
Why?
|
| Fetus | 1 | 2017 | 228 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 599 | 0.140 |
Why?
|
| Prognosis | 1 | 2021 | 2105 | 0.140 |
Why?
|
| Anticholesteremic Agents | 1 | 2015 | 34 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 97 | 0.140 |
Why?
|
| Dyslipidemias | 1 | 2015 | 40 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 265 | 0.140 |
Why?
|
| Cholesterol | 1 | 2015 | 139 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 128 | 0.130 |
Why?
|
| Primitive Streak | 1 | 2014 | 1 | 0.130 |
Why?
|
| Somites | 1 | 2014 | 7 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2015 | 477 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1143 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 167 | 0.120 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 21 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 252 | 0.120 |
Why?
|
| Receptor, Insulin | 1 | 2012 | 44 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2017 | 640 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2012 | 60 | 0.120 |
Why?
|
| Bone Diseases | 1 | 2012 | 107 | 0.110 |
Why?
|
| Pregnancy | 1 | 2017 | 2432 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 3439 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 412 | 0.090 |
Why?
|
| Child | 1 | 2020 | 6933 | 0.090 |
Why?
|
| Apoptosis | 1 | 2012 | 1356 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 217 | 0.070 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 134 | 0.050 |
Why?
|
| Carboplatin | 1 | 2019 | 54 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 48 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2019 | 106 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2021 | 248 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 138 | 0.040 |
Why?
|
| Chemokine CCL22 | 1 | 2017 | 2 | 0.040 |
Why?
|
| Phosphopeptides | 1 | 2017 | 5 | 0.040 |
Why?
|
| src Homology Domains | 1 | 2017 | 9 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 2017 | 10 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2017 | 83 | 0.040 |
Why?
|
| Biomimetic Materials | 1 | 2017 | 13 | 0.040 |
Why?
|
| Fibronectins | 1 | 2017 | 40 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 34 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 158 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 159 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2017 | 71 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2017 | 124 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 348 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 269 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 138 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2016 | 2 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 545 | 0.040 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2016 | 8 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 132 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2016 | 84 | 0.040 |
Why?
|
| Cadherins | 1 | 2016 | 79 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 522 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 842 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 76 | 0.030 |
Why?
|
| Triazines | 1 | 2012 | 30 | 0.030 |
Why?
|
| Thiazoles | 1 | 2012 | 64 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1067 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 317 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2012 | 119 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 521 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 438 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2012 | 199 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2012 | 721 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1700 | 0.020 |
Why?
|